Search results for "LIVER"

showing 10 items of 4961 documents

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Novel cytokine-targeted therapies and intestinal inflammation

2009

Several cytokines have been identified as critical mediators of chronic inflammation in inflammatory bowel disease (IBD) and biological therapies that target these molecules have been developed during recent years. Thereby, anti-TNF agents have noticeably improved the treatment of patients with IBD in comparison to conventional therapy. Furthermore, initial clinical trials showed promising results with anti-IL-6 and anti-IL-12/IL-23 agents. In addition to these well-known mediators of IBD, various novel cytokines have been described as critical during the pathogenesis of IBD in recent experimental studies and therapeutic targeting of these cytokines could provide new strategies for human di…

medicine.medical_treatmentInflammationTherapeutic targetingInflammatory bowel diseaseAntibodiesPathogenesisDrug Delivery SystemsIntestinal inflammationDrug DiscoverymedicineAnimalsHumansIntestinal MucosaPharmacologyBiological therapiesbusiness.industryModels ImmunologicalColitisInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesIntestinesClinical trialDisease Models AnimalCytokineImmunologyCytokinesmedicine.symptombusinessCurrent Opinion in Pharmacology
researchProduct

Regulation of cytochrome P450 IID by acute phase mediators in C3H/HeJ mice.

1992

Abstract Cytochrome P450 IID6 is a drug metabolizing enzyme and the major target antigen in LKM-1 antibody positive chronic active hepatitis. The histological hallmark of chronic active hepatitis is a lymphocytic infiltrate in the liver. It is unknown whether and how cytokines produced and secreted by these tissue infiltrating mononuclear cells regulate the cellular expression of cytochrome P450 IID6. To study the effect of interleukin 1, tumor necrosis factor and interleukin 6 on the hepatocellular RNA expression of cytochrome P450 IID, we injected each of the cytokines in C3H HeJ mice. We found a time-dependent suppression of the cytochrome in the liver. Six hours after the intraperitonea…

medicine.medical_treatmentIntraperitoneal injectionBiophysicsBiochemistryMixed Function OxygenasesMiceCytochrome P-450 Enzyme SystemmedicineEscherichia coliAnimalsHumansInterleukin 6Molecular BiologyHepatitisMice Inbred C3HbiologyInterleukin-6Tumor Necrosis Factor-alphaCytochrome P450InterleukinCell Biologymedicine.diseaseBlotting NorthernRecombinant ProteinsEndotoxinsCytokineCytochrome P-450 CYP2D6LiverImmunologybiology.proteinRNATumor necrosis factor alphaFemaleAntibodyInterleukin-1Biochemical and biophysical research communications
researchProduct

Guillain-Barré syndrome after orthotopic liver transplantation: A clinical manifestation of immune reconstitution inflammatory syndrome?

2018

Guillain-Barrè Syndrome, as part of the spectrum of dysimmune neuropathies, is unexpected to occur in immunocompromised hosts. We describe a clinical case of Guillain-Barrè syndrome, occurred a few weeks after a liver transplant, and we postulate that our case would satisfy all requirements to explain this peripheral nervous system complication as a clinical manifestation of an Immune reconstitution inflammatory syndrome. In this setting of liver transplantation, complicated by potentially multiple infective triggers, reduction of immunosuppression and reversal of pathogen-induced immunosuppression, through antimicrobial therapy, may have led to pro-inflammatory response. The pro-inflammato…

medicine.medical_treatmentLiver transplantationGuillain-Barre SyndromeTacrolimus030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineImmune systemImmune reconstitution inflammatory syndromemedicineHumansImmune reconstitution inflammatory syndromeAcute demyelinating polyneuropathyImmunosuppression TherapyInflammationLiver transplantationGuillain-Barre syndromebusiness.industryImmunosuppressionGeneral Medicinemedicine.diseaseGuillain-Barré syndromeTacrolimusPathophysiologyTacrolimuImmunologyAcute demyelinating polyneuropathy; Guillain-Barré syndrome; Immune reconstitution inflammatory syndrome; Liver transplantation; TacrolimusSurgeryFemaleNeurology (clinical)Complicationbusiness030217 neurology & neurosurgery
researchProduct

Fat-storing cells of the rat liver synthesize and secrete C1-esterase inhibitor; modulation by cytokines.

1992

During liver fibrogenesis, fat-storing cells transform into myofibroblast-like cells and produce increasing amounts of extracellular matrix proteins. Because fat-storing cells produce α2-macroglobulin, an important serine protease inhibitor (serpin), we investigated whether fat-storing cells also synthesize C1-esterase inhibitor, another important serpin. C1-esterase inhibitor synthesis was studied in rat fatstoring cells at day 0, 3 and 7 after isolation by biosynthetic labeling, immunoprecipitation and sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Messenger RNA was examined by Northern-blot analysis. C1-esterase inhibitor gene expression and synthesis were detectable in fresh…

medicine.medical_treatmentMolecular Sequence DataIn situ hybridizationSerpinBiologyComplement C1 Inactivator ProteinsDexamethasonechemistry.chemical_compoundInterferon-gammaGene expressionmedicineAnimalsSecretionRNA MessengerCells CulturedMessenger RNAHepatologyBase SequenceNucleic Acid HybridizationRats Inbred StrainsTunicamycinBlotting NorthernLipid MetabolismMolecular biologyRatsUp-RegulationCytokineBiochemistrychemistryLiverCell cultureElectrophoresis Polyacrylamide GelFemaleHepatology (Baltimore, Md.)
researchProduct

A hyaluronic acid/cyclodextrin based injectable hydrogel for local doxorubicin delivery to solid tumors

2020

Localized delivery of anticancer drugs is often the most useful therapeutic approach for the treatment of solid tumors. The use of injectable polymeric systems that maximize drug concentration in the proximal area of the tumor represents an extremely advantageous therapeutic strategy. Here, the development of an injectable in situ forming hydrogel was accomplished by exploiting the azo-type Michael reaction between an amine derivative of hyaluronic and vinylsulfone functionalized -cyclodextrins complexing doxorubicin. This injectable system can be easily prepared and administered with timelines compatible with normal operating room procedures, as demonstrated by rheological tests. In vitro…

medicine.medical_treatmentPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAnimal modelIn vivoNeoplasmsHyaluronic acidmedicineAnimalsDoxorubicinHyaluronic Acidchemistry.chemical_classificationCyclodextrinsChemotherapyCyclodextrinChemistryHydrogels021001 nanoscience & nanotechnologyIn vitroDrug concentrationDoxorubicinLocalized chemotherapy hyaluronic acid cyclodextrins in situ forming hydrogel DoxorubicinSettore CHIM/09 - Farmaceutico Tecnologico Applicativo0210 nano-technologyBiomedical engineeringmedicine.drug
researchProduct

Delivery of siHIF‐1α to Reconstruct Tumor Normoxic Microenvironment for Effective Chemotherapeutic and Photodynamic Anticancer Treatments

2021

The tumor hypoxic microenvironment not only induces genetic and epigenetic changes in tumor cells, immature vessels formation for oxygen demand, but also compromises the efficiency of therapeutic interventions. On the other hand, conventional therapeutic approaches which kill tumor cells or destroy tumor blood vessels to block nutrition and oxygen supply usually facilitate even harsher microenvironment. Thus, simultaneously relieving the strained response of tumor cells and blood vessels represents a promising strategy to reverse the adverse tumor hypoxic microenvironment. In the present study, an integrated amphiphilic system (RSCD) is designed based on Angiotensin II receptor blocker cand…

medicine.medical_treatmentPhotodynamic therapy02 engineering and technology010402 general chemistry01 natural sciencesBiomaterialsNeovascularizationchemistry.chemical_compoundIn vivoCell Line TumorTumor MicroenvironmentmedicineHumansGeneral Materials ScienceRNA Small InterferingHypoxiaChemotherapyTumor microenvironmentGeneral ChemistryHypoxia-Inducible Factor 1 alpha Subunit021001 nanoscience & nanotechnologyCell HypoxiaIn vitro0104 chemical sciencesOxygenchemistryDrug deliveryCancer researchmedicine.symptomGrowth inhibition0210 nano-technologyBiotechnologySmall
researchProduct

Hepatocyte growth factor induces MAT2A expression and histone acetylation in rat hepatocytes: role in liver regeneration 1

2001

SPECIFIC AIMSWe have studied the molecular mechanisms and mediators behind the induction of methionine adenosyltransferase 2 A (MAT2A) gene expression in the regenerating rat liver after partial he...

medicine.medical_treatmentRNABiologyBiochemistryMolecular biologyLiver regenerationHistoneAcetylationMethionine AdenosyltransferaseGene expressionGeneticsmedicinebiology.proteinHepatocyte growth factorHepatectomyMolecular BiologyBiotechnologymedicine.drugThe FASEB Journal
researchProduct

Spontaneous labour at term is associated with fetal monocyte activation.

1999

SUMMARYThe aetiology of both term and preterm labour remains incompletely understood. Maternal infectious diseases as well as intra-uterine infections were shown to be a well established cause of uncontrollable preterm delivery, indicating that inflammatory reactions, regulated by maternal immunecompetent cells, are implicated in labour-promoting mechanisms. To investigate the possibility that the activation of the fetal immune system may be involved in labour induction, we examined cytokine production patterns of different cord blood cell populations obtained from neonates after spontaneous onset of normal term labour and vaginal delivery (n = 25), vaginal delivery but induced term labour …

medicine.medical_treatmentT cellImmunologyInflammationGestational AgeBetamethasoneMonocytesMagnesium SulfateImmune systemFetusObstetric Labor PrematurePregnancymedicineImmunology and AllergyHumansLabor InducedLungreproductive and urinary physiologyFenoterolFetusLabor Obstetricbusiness.industryVaginal deliveryCesarean SectionInterleukin-6MonocyteInfant NewbornDelivery ObstetricFetal Bloodmedicine.anatomical_structureCytokineTocolytic AgentsCord bloodImmunologyFemaleOriginal Articlemedicine.symptombusinessClinical and experimental immunology
researchProduct

T cell–mediated response to SARS‐CoV‐2 in liver transplant recipients with prior COVID‐19

2021

Abstract Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2‐specific T‐cell‐mediated immunity (SARS‐CoV‐2‐CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS‐CoV‐2‐CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)‐γ FluoroSpot assay after a median of 103 days from COVID‐19 diagnosis. Serum SARS‐CoV‐2 IgG antibodies were measured by ELISA. A control group of non‐transplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post‐transplant SARS‐CoV‐2‐CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN‐γ‐producing CD4+ than …

medicine.medical_treatmentT cellT-LymphocytesLiver transplantationAntibodies ViralCOVID-19 TestingAntigenImmunityImmunology and AllergyMedicineHumansPharmacology (medical)Transplantationbiologybusiness.industrySARS-CoV-2COVID-19ImmunosuppressionOriginal ArticlesTransplant RecipientsLiver Transplantationmedicine.anatomical_structureImmunologybiology.proteinOriginal ArticleAntibodybusinessFluoroSpotCD8American Journal of Transplantation
researchProduct